- Conditions
- Lethal Means Safety, Brief Intervention, Concern Significant Others
- Interventions
- The Family Firearms Secure storage Training (FFAST) Intervention, Health and Stress Counseling
- Behavioral
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 176 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 767
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Type 2 Diabetes
- Interventions
- Dapagliflozin, Dapagliflozin placebo, Metformin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 77 Years
- Enrollment
- 1,067 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 38
- States / cities
- Phoenix, Arizona • Tempe, Arizona • Fresno, California + 31 more
- Conditions
- Polycystic Kidney, Autosomal Dominant
- Interventions
- Tolvaptan
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2010
- U.S. locations
- 11
- States / cities
- Denver, Colorado • Jacksonville, Florida • Atlanta, Georgia + 8 more
- Conditions
- Hypercholesterolemia
- Interventions
- PBO, 200mg PF-04950615 (RN316), 300mg PF-04950615 (RN316), PF-04950615
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 354 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 74
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Tucson, Arizona + 59 more
- Conditions
- Breast Cancer Screening
- Interventions
- Mammography decision aid, Home safety pamphlet
- Other
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Other
- Eligibility
- 75 Years to 89 Years · Female only
- Enrollment
- 541 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 4
- States / cities
- Boston, Massachusetts • Chapel Hill, North Carolina
- Conditions
- Autism Spectrum Disorder
- Interventions
- Functional Neurogenesis Stimulation Therapy, placebo control group
- Device · Other
- Lead sponsor
- Neurocytonix, Inc.
- Industry
- Eligibility
- 3 Years to 12 Years
- Enrollment
- 256 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Rockville, Maryland
- Conditions
- Chemotherapy-induced Peripheral Neuropathy
- Interventions
- Memantine XR-pregabalin combination therapy
- Drug
- Lead sponsor
- Saint John's Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 1
- States / cities
- Santa Monica, California
- Conditions
- Suicide, Mental Health Disorder, Anhedonia
- Interventions
- ViraBrite nudges
- Behavioral
- Lead sponsor
- Ksana Health
- Industry
- Eligibility
- 13 Years to 18 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Type 1 Diabetes
- Interventions
- DiaBetter Together, Peer Mentor Delivery
- Behavioral
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 17 Years to 35 Years
- Enrollment
- 144 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- PARKINSON DISEASE (Disorder)
- Interventions
- Steady Together at home fall prevention program
- Other
- Lead sponsor
- Cleveland State University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Beachwood, Ohio
- Conditions
- Breast Cancer
- Interventions
- Lumpectomy without sentinel node biopsy
- Procedure
- Lead sponsor
- Cedars-Sinai Medical Center
- Other
- Eligibility
- 18 Years and older · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Suicidal Ideation, Suicide Attempt, Safety Plan, Depression / Major Depressive Disorder, Hopelessness
- Interventions
- CAMS Brief Intervention, Stanley-Brown Safety Planning Intervention
- Behavioral
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 118 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Suicide and Self-harm, Suicide, Suicide, Attempted, Suicidal Ideation
- Interventions
- Mobile Application to Prevent Suicide (MAPS)
- Behavioral
- Lead sponsor
- Butler Hospital
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 2
- States / cities
- Providence, Rhode Island
- Conditions
- Overweight, Obesity
- Interventions
- NNC0247-0829, Placebo (NNC0247-0829)
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 103 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Perioperative Medication Errors, Perioperative Adverse Medication Events
- Interventions
- Electronic Clinical Decision Support Application
- Other
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Friedreich's Ataxia
- Interventions
- Interferon γ-1b
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 10 Years to 26 Years
- Enrollment
- 86 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Gainesville, Florida • Iowa City, Iowa + 1 more
- Conditions
- Adolescent Behavior
- Interventions
- Sexual Health, Alcohol Prevention, Teen Driving
- Behavioral
- Lead sponsor
- Children's Hospital of Philadelphia
- Other
- Eligibility
- 14 Years to 17 Years
- Enrollment
- 348 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Solid Tumors
- Interventions
- Epacadostat, Nivolumab, Ipilimumab, Lirilumab
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 5
- States / cities
- Birmingham, Alabama • Los Angeles, California • Santa Monica, California + 2 more
- Conditions
- Hyper IgE Syndrome From STAT3 Mutation, Job s Syndrome, HIES, Lupus, Atopic Dermatitis
- Interventions
- baricitinib
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 12 Years to 120 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Diabetic Macular Edema
- Interventions
- RO7446603, Aflibercept, Faricimab
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 388 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 70
- States / cities
- Phoenix, Arizona • Springdale, Arkansas • Campbell, California + 60 more
- Conditions
- Advanced Relapsed Tumors, Refractory Solid Tumors
- Interventions
- OMP-131R10, FOLFIRI
- Drug
- Lead sponsor
- OncoMed Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 7
- States / cities
- San Francisco, California • Aurora, Colorado • New Haven, Connecticut + 4 more
- Conditions
- Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IVA Gastric Cancer AJCC v8, Clinical Stage IVB Gastric Cancer AJCC v8, Malignant Uterine Neoplasm, Metastatic Appendix Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Gastric Carcinoma, Metastatic Malignant Neoplasm in the Peritoneum, Metastatic Malignant Solid Neoplasm, Metastatic Ovarian Carcinoma, Pathologic Stage IV Gastric Cancer AJCC v8, Peritoneal Carcinomatosis, Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8, Stage IV Appendix Carcinoma AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Uterine Corpus Cancer AJCC v8, Stage IVA Appendix Carcinoma AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVA Ovarian Cancer AJCC v8, Stage IVA Uterine Corpus Cancer AJCC v8, Stage IVB Appendix Carcinoma AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVB Ovarian Cancer AJCC v8, Stage IVB Uterine Corpus Cancer AJCC v8, Stage IVC Appendix Carcinoma AJCC v8, Stage IVC Colorectal Cancer AJCC v8
- Interventions
- Biopsy, Cisplatin, Doxorubicin, Fluorouracil, Intraperitoneal Chemotherapy, Irinotecan, Leucovorin, Mitomycin, Oxaliplatin, Quality-of-Life Assessment, Questionnaire Administration
- Procedure · Drug · Device + 1 more
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2028
- U.S. locations
- 3
- States / cities
- Duarte, California • Jacksonville, Florida • Greenlawn, New York
- Conditions
- PIK3CA-related Overgrowth Spectrum (PROS)
- Interventions
- Alpelisib
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 2 Years to 100 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Mantle Cell Lymphoma, Peripheral T-cell Lymphoma (PTCL), Cutaneous T-cell Lymphoma (CTCL), Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Follicular Lymphoma, Marginal Zone Lymphoma, Hodgkin Lymphoma, Waldenstrom Macroglobulinemia, DLBCL
- Interventions
- L-Bcl-2 antisense oligonucleotide
- Drug
- Lead sponsor
- Bio-Path Holdings, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 5
- States / cities
- Augusta, Georgia • Valhalla, New York • Nashville, Tennessee + 2 more